Items

• Risk stratification in 3-vessel coronary artery disease: Applying the SYNTAX Score II in the Heart Team Discussion of the SYNTAX II trial. (2015-11)

  B. Stanetić, C. Campos, V. Farooq, S. Walsh, Y. Ishibashi, Y. Onuma, H. Garcia-Garcia, J. Escaned, A. Banning, P. Serruys, Risk stratification in 3-vessel coronary artery disease: Applying the SYNTAX Score II in the Heart Team Discussion of the SYNTAX II trial., CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 15, No. 86, pp. 229 - 238, Nov, 2015

• Rationale and design of the SYNTAX II trial evaluating the short to long-term outcomes of state-of-the-art percutaneous coronary revascularisation in patients with de novo three-vessel disease. (2016-06)

  J. Escaned, A. Banning, V. Farooq, M. Echavarria-Pinto, Y. Onuma, N. Ryan, R. Calvacante, C. Campos, B. Stanetić, Y. Ishibashi, P. Suwannasom, A. Kappetein, D. Taggart, M. Morel, G. van Es, P. Serruys, Rationale and design of the SYNTAX II trial evaluating the short to long-term outcomes of state-of-the-art percutaneous coronary revascularisation in patients with de novo three-vessel disease., EuroIntervention, Vol. 12, No. 2, pp. 224 - 234, Jun, 2016

• Risk Stratification in 3- Vessel Coronary Artery Disease: Applying the SYNTAX Score II in the Heart Team Discussion of the SYNTAX II Trial. (2016)

  C. Campos, B. Stanetić, V. Farooq, S. Walsh, Y. Ishibashi, Y. Onuma, H. Garcia-Garcia, J. Escaned, A. Banning, P. Serruys, Risk Stratification in 3- Vessel Coronary Artery Disease: Applying the SYNTAX Score II in the Heart Team Discussion of the SYNTAX II Trial., 2016